Profile: Novo Nordisk A/S (NVO)
10 Mar 2014
Novo Nordisk A/S, incorporated in 1989, is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition, it has is engaged in areas, such as haemophilia, growth hormone therapy and hormone replacement therapy. It manufactures and markets pharmaceutical products and services to patients, the medical profession and society. The Company operates in two segments: diabetes care and biopharmaceuticals. It operates in four geographical regions North America: the United States of America and Canada; Europe: the European Union, EFTA, Albania, Bosnia-Herzegovina, Croatia, Macedonia, Serbia, Montenegro and Kosovo; Japan and Korea, and International Operations: all other countries, including China. its products include Victoza, NovoNorm/Prandin/PrandiMet, NovoSeven, Norditropin and other products. In February 2014, Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
The diabetes care segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, and oral antidiabetic products (OAD). It also covers other protein-related products and projects (such as glucagon and protein-related delivery systems) and oral antidiabetic drugs. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas. The major production facilities owned by the Company are located at a number of sites in Denmark, and the international production or processing facilities are located in the United States, France, Japan, China and Brazil.
Novo Nordisk A/S
Company Web Links
- UPDATE 1-NORDIC STOCKS-Factors to watch on March 6
- Lilly weekly diabetes drug as effective as market leader Victoza-study
- UPDATE 1-Lilly weekly diabetes drug as effective as market leader Victoza-study
- Lilly weekly diabetes drug succeeds vs market leader Victoza -study
- BRIEF-Innate Pharma buys rights to drug from Novo Nordisk